{"id":"NCT01277042","sponsor":"GlaxoSmithKline","briefTitle":"Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)","officialTitle":"Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK 580299) in Healthy Adult Chinese Female Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02-17","primaryCompletion":"2011-09-26","completion":"2012-02-28","firstPosted":"2011-01-14","resultsPosted":"2013-12-03","lastUpdate":"2018-08-17"},"enrollment":1212,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Papillomavirus"],"interventions":[{"type":"BIOLOGICAL","name":"GSK580299 (CervarixTM)","otherNames":[]},{"type":"BIOLOGICAL","name":"Engerix-BTM","otherNames":[]}],"arms":[{"label":"Cervarix Group","type":"EXPERIMENTAL"},{"label":"Engerix Group","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to evaluate the immunogenicity and safety of GSK Biologicals' human papillomavirus (HPV) vaccine in adult female subjects aged 26-45 years. One group of subjects will receive the HPV vaccine and the other group will receive an active control (GSK Biologicals' hepatitis B vaccine). Immunogenicity data of the HPV group will be compared with those from the HPV group included in the NCT00779766 study (aged 18-25 years).","primaryOutcome":{"measure":"Number of Seroconverted Subjects Against Human Papillomavirus-16 (HPV-16) and HPV-18","timeFrame":"One month after third vaccination (Month 7)","effectByArm":[{"arm":"Cervarix Group","deltaMin":345,"sd":null},{"arm":"Engerix Group","deltaMin":67,"sd":null}],"pValues":[]},"eligibility":{"minAge":"26 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["25424785"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":606},"commonTop":["Pain","Redness","Swelling","Fatigue","Headache"]}}